Effect of telehealth interventions on adherence to endocrine therapy among patients with breast cancer: a systematic review and meta-analysis

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA A Cancer J Clin 71 209-249

[2] Ferlay J(2019)Breast cancer treatment: a review Jama 321 288-300

[3] Siegel RL(2019)Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update J Clin Oncol 37 423-438

[4] Waks AG(2011)Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 771-784

[5] Winer EP(2022)Breast cancer survivors’ lived experience of adjuvant hormone therapy: a thematic analysis of medication side effects and their impact on adherence Front Psychol 13 22-35

[6] Burstein HJ(2022)Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: a systematic review Breast 62 323-e313

[7] Lacchetti C(2003)Adherence to long-term therapies: evidence for action Eur J Cardiovasc Nurs 2 e303-15

[8] Anderson H(2021)Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer Lancet Oncol 22 8-1180

[9] Davies C(2021)Adjuvant endocrine therapy for premenopausal women with breast cancer: patient adherence and physician prescribing practices in Mexico Breast 59 1172-4561

[10] Godwin J(2013)The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study Br J Cancer 109 4548-276

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA A Cancer J Clin 71 209-249

[2] Ferlay J(2019)Breast cancer treatment: a review Jama 321 288-300

[3] Siegel RL(2019)Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update J Clin Oncol 37 423-438

[4] Waks AG(2011)Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 771-784

[5] Winer EP(2022)Breast cancer survivors’ lived experience of adjuvant hormone therapy: a thematic analysis of medication side effects and their impact on adherence Front Psychol 13 22-35

[6] Burstein HJ(2022)Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: a systematic review Breast 62 323-e313

[7] Lacchetti C(2003)Adherence to long-term therapies: evidence for action Eur J Cardiovasc Nurs 2 e303-15

[8] Anderson H(2021)Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer Lancet Oncol 22 8-1180

[9] Davies C(2021)Adjuvant endocrine therapy for premenopausal women with breast cancer: patient adherence and physician prescribing practices in Mexico Breast 59 1172-4561

[10] Godwin J(2013)The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study Br J Cancer 109 4548-276